Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01571284 · ClinicalTrials.gov registry record · Phase 3
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 781
- Enrollment target
NCT01571284 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 781 participants.
The verdict
NCT01571284, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 781 participants
- Enrollment target
Study Summary
Primary Objective: To provide metastatic colorectal cancer participants with access to aflibercept and to document the overall safety in these participants Secondary Objective: To document the Health-Related Quality of Life of aflibercept in this participants population
Interventions
- DRUG FOLFIRI
- DRUG AFLIBERCEPT AVE0005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 781 participants |
| Start Date | 2012-05-30 |
| Est. Completion | 2017-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01571284
The ClinicalTrials.gov registry entry for NCT01571284 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 781 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FOLFIRI is the first listed.
NCT01571284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01571284 about?
NCT01571284 is a clinical study titled "Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen". Primary Objective: To provide metastatic colorectal cancer participants with access to aflibercept and to document the overall safety in these participants Secondary Objective: To document the Health-Related Quality of Life of aflibercept in this participants population
What is the current status of trial NCT01571284?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 781 participants. The study started on 2012-05-30. Estimated completion is 2017-01-31.
What interventions are being tested in trial NCT01571284?
The interventions under investigation include: FOLFIRI (DRUG), AFLIBERCEPT AVE0005 (DRUG).
Who is sponsoring clinical trial NCT01571284?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.